Product Name: Recombinant Human EDIL3 (C-6His)
Catalog #: PHH0558

Summary

Name	EDIL3/EGF-like repeats and discoidin I-like domains 3
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human EGF-Like Repeat And Discoidin I-Like Domain-Containing Protein 3 is produced by our Mammalian expression system and the target gene encoding Asp24-Glu480 is expressed with a 6His tag at the C-terminus.
Accession #	O43854-1
Host	Human Cells
Species	Human
Predicted Molecular Mass	53.09 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM Citrate, 6% Trehalose, 4% Mannitol, 100mM NaCl, 0.05% Tween 80, pH 5.0.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Product Name: Recombinant Human EDIL3 (C-6His)
Catalog #: PHH0558

Background

Alternative Names	EGF-like repeat and discoidin I-like domain-containing protein 3; Developmentally-regulated endothelial cell locus 1 protein; Integrin-binding protein DEL1; Edil3; Del1; EDIL3
Background	EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3 (EDIL3) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development. EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. EDIL3 has been found to be re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis. EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression. EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion. Human EDIL3 is synthesized as a precursor with a 16 amino acid signal sequence and a 464 amino acid mature chain.

Note

For Research Use Only , Not for Diagnostic Use.